Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

nding the current product label into adult AML. Preliminary data has been accepted for presentation at ASCO this spring and a supplemental new drug application (sNDA) for clofarabine is expected to be filed in the second half of this year. It is possible that data from this study also could be considered for part of a new filing with EMEA.

Evoltra is currently indicated for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients who have relapsed or are refractory to at least two prior regimens. The withdrawal of the European application of Evoltra in adult AML has no consequences for patients enrolled in current clinical trials or compassionate use programs.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including the expected results of the data generated from clofarabine clinical trials, the presentation and use of this data to support regulatory filings, and t
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 Whitehouse Laboratories has formally ... Stability Testing and Package Test Capacity. Responding to growing ... a dramatic increase in environmental chamber storage space that ... and aging samples to be securely held on site ... capital expenditure has already taken place with the recent ...
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... 8:30 a.m. ET in Boston, MA. ... available on the "Investors & Media" section of the Company,s ... the Isis website within 48 hours and will be archived ...
(Date:10/30/2014)... of the key challenges in the development of quantum ... , In a paper published today (28 October) in ... show how to make a new type of flexibly ... such as high-precision sensors and specialised superfast computers, often ... the methods for trapping these tiny particles are hugely ...
(Date:10/27/2014)... The new research report, “Gas ... Medium), Sub-type (Primary & Secondary), and End-User (Transmission ... & Power Generation) - Trends and Forecasts to ... analysis and forecasting of the market size. , ... 52 Figures spread through 146 Pages and in-depth ...
Breaking Biology Technology:Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... AMSTERDAM, October 13 Amsterdam Molecular,Therapeutics ... gene therapy,announced today that the European Medicines Agency has ... for the treatment of,Duchenne muscular dystrophy. , ... (DMD) entitles,AMT to ten year market exclusivity in Europe ...
... HAIKOU CITY, China, Oct. 12 ... CPHI ), which develops,manufactures, and markets specialty pharmaceutical ... the Roth China Conference, to be held,October 12-14, 2009, ... participate in one-on-one meetings with conference attendees throughout,the three-day ...
... 12 Dr. Michael Merzenich , PhD ... brain plasticity expert and tech entrepreneur - was ... Washington, D.C. Also a member of the National Academy of ... scientists and doctors in the U.S. who have been selected ...
Cached Biology Technology:AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 2AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 3Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research 2Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research 3
(Date:10/30/2014)... UT Arlington bioengineering professor has received a $1.04 ... to regenerate cartilage tissue and reduce osteoarthritis using ... injection of microscaffolding made of biodegradable polymers., Liping ... the bioengineering department, said the research is primarily ... on the battlefield., "We,ve found that if we ...
(Date:10/30/2014)... Philadelphia, PA, October 30, 2014 – Bacteria in ... are critical for digestion. Yet, these same bacteria ... system if they penetrate the gut and enter ... natural response to protect the body, chronic or ... diseases. Prior research has established the involvement of ...
(Date:10/29/2014)... by unconventional oil and gas production are well over ... the open access journal Environmental Health . High ... The study is the first to be based on ... and could be used to supplement official air-quality monitoring ... that do not readily flow to the surface. This ...
Breaking Biology News(10 mins):UTA researcher uses microscaffolding injections to mend cartilage, prevent osteoarthritis 2Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3
... Chicago, IllinoisJune 22, 2010"Seasick: Ocean Change and the ... in the US by the University of Chicago Press, ... in Environmental Reporting. Awarded by the Metcalf Institute for ... of the environment and recognizes reporting that has the ...
... puzzled over why a baby,s brain is particularly flexible ... have to learn a lot? A group of researchers ... Institute for Dynamics and Self-Organization in Gttingen, the Schiller ... put forward a new explanation: Maybe it is because ...
... (June 20, 2010) By emulating nature,s design principles, ... Engineering, Harvard Medical School and Dana-Farber Cancer Institute has ... be programmed to move and change shape on demand. ... highly suitable for medical applications because DNA is both ...
Cached Biology News:Growing brain is particularly flexible 2Researchers create self-assembling nanodevices that move and change shape on demand 2
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Mouse polyclonal antibody raised against a partial recombinant CD320. NCBI Entrez Gene ID = 51293...
Mouse monoclonal antibody raised against a partial recombinant CHD8. NCBI Entrez Gene ID = CHD8...
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Biology Products: